Acute pancreatitis as initial manifestation in an adult patient with focal proliferative necrotizing purpura nephritis  by Liu, Dong et al.
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etters to the Editor - Case Report
cute  pancreatitis  as  initial  manifestation  in an
dult patient  with  focal  proliferative  necrotizing
urpura nephritisancreatitis  aguda  como  manifestación  inicial  en  un  paciente  adulto
on  purpura  y  glomerulonefritis  necrosante  proliferativa  focalear Editor,
enoch–Schönlein purpura (HSP) is a generalized vasculitis,
hich could cause a large variety of symptoms in different
rgans. Acute pancreatitis is an inﬂammatory disorder and
ay be life-threatening if it is severe. HSP could cause the
cute pancreatitis rarely. It tends to develop in the ﬁrst week
f the illness after characteristic purpura, or develop later.1
xceptionally, acute pancreatitis developed during the course
f HSPN as an initial presenting feature before the typical rash.
ere we  report an adult patient with HSPN presenting after the
cute pancreatitis.
A 19-year-old man  was admitted to our hospital with the
hief complaint of “abdominal pain and abnormal urine test
or 1 month, erythematosus purpura over legs for 5 days”.
e received the treatment for pancreatitis in the local hos-
ital. However, the pancreatitis did not get remission. On
dmission of our hospital, the patient had a normal blood
ressure and respiratory rate. There was a diffuse purpuric
ash located over the legs. Abdominal examination showed
enderness in all quadrants with rebound tenderness. There
as no hepatosplenomegaly, and bowel sounds were nor-
al. Blood testing showed hemoglobin (101 g/l), white cell
ount (19.6 × 109 g/l), neutrophil (9.7 × 109 g/l). Erythrocyte sed-
mentation rate and C-reactive protein were signiﬁcantly
igh at 29 mm/h  and 100.3 mg/l, respectively. Serum testing
howed glucose (3.3 mmol/l), urea (6.31 mmol/l), creatinine
52 umol/l), albumin (28.5 g/l), total cholesterol (4.1 mmol/l),
nd triglyceride (1.6 mmol/l). Serum amylase (332 U/l) and
ipase (85.2 U/l) were increased. Urinary sediment examina-
ion showed microscopic hematuria. The proteinuria of 24 h
s 2.48 g/2 L. Rheumatoid factor and complements (C3, C4)
ere within the normal range, and antinuclear antibodies,anti-DNA, antiphospholipids, antineutrophil cytoplasmic
antibodies, and hepatitis viral markers were negative. Abdom-
inal ultrasound showed a peritoneal effusion. Abdominal
computed tomography (CT) scan noted an edematous pan-
creas (Fig. 1).
The result of renal biopsy was focal proliferative necro-
tizing purpura nephritis. Focal granular staining for IgA and
C3 in the mesangium was shown using immunoﬂuorescence
staining. By light microscopy, glomeruli showed a mild hyper-
cellularity in mesangial cells and matrix, focal endocapillary
hypercellularity, eight crescents of 10 glomerulis, 1 necrosis
of capillary loop. There is interstitial edema and inﬂamma-
tion composed mainly of mononuclear leukocytes and tubular
epithelial injury (Fig. 2). The result of the light microscopy was
conﬁrmed by the electron microscopy.
The patient was diagnosed as purpura nephritis com-
plicated by acute pancreatitis. He was started on therapy
with methylprednisolone 40 mg/d intravenously for 5 days
before the renal biopsy result. Afterwards, 0.5 g bolus of
methylprednisolone was given intravenously for 3 days and
after that prednisone orally (30 mg/day) and MMF  orally
(1.5 mg/day). Abdominal pain disappeared at the third day of
the treatment and the pancreas was normal after two weeks’
treatment. After 1-year follow-up, the patient recovered well
with prednisone (10 mg/day) and MMF (0.25 mg/d), and renal
function was normal, proteinuria was less than 150 mg/day,
and abdominal CT scan was normal.
The association between pancretitis and Henoch–
Schönlein Purpura Nephritis is rare. In our case, purpura
nephritis complicated by acute pancreatitis was showed in
this 19-year-old man. HSP is a rare cause of acute pancre-
atitis that can occur before or after the characteristic rash.
In our case, the symptoms occurred before the rash. The
502  n e f r o l o g i a 2 0 1 5;
Fig. 1 – Edematous pancreas in abdominal CT scan.pancreatitis tends to develop on the ﬁrst day of the illness
but may develop as late as day 75.2 Acute pancreatitis is
presumed to be caused by vasculitic involvement of the
pancreas.
The clinical feature of HSP nephritis is quite variable.
The pathology of this patient showed a mild hypercel-
lularity in mesangial cells and matrix, focal endocap-
illary hypercellularity, eight crescents of ten glomerulis,
1 necrosis of capillary loop. In the literature, only two
Fig. 2 – Crescents observed by light microscopy in Masson
stained section (upper one, 400) and PAS stained section
(lower one, 400).
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cases got renal biopsy of purpura nephritis with pan-
cretitis. One case showed moderate-to-severe increase
of mesangial matrix with crescent formation3 and one
case showed endocapillary proliferative glomerulonephritis.2
There is no special feature in the pathology of those
patients.
Steroids have been used to treat HSP patients with
pancretitis.4–7 For most HSP related pancretitis without
nephritis, parenteral nutrition and Nasogastric suction was
used to treat the pancretitis,8,9 and the outcome of pancreti-
tis improved. In our case, the patient’s pancretitis did not
improve with the supportive treatment; however, the symp-
toms of pancretitis disappeared with the steroids usage. In
the literature, two patients were diagnosed as HSP related
pancretitis with nephritis. In the study by Frirui et al., kidney
biopsy showed endocapillary proliferative glomerulonephri-
tis and the patient was given 1 g bolus methylprednisolone
intravenously for 3 days and after that prednisone orally
(60 mg/day).2 And in the study by Nie et al., as HSP nephri-
tis (severe) was conﬁrmed, intravenous methylprednisolone
(500 mg/d) was given to the patient for 3 days followed by  oral
dehydrocortisone of 30 mg/d.3 The two patients got complete
remission in pancreas and kidney.
HSP is a rare and benign cause of acute pancreatitis.
This complication could occur before the characteristic rash
and shown as an initial manifestation of HSPN. Steroids
could improve the outcome of the HSPN patients with
pancreatitis.
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esponse  to  acetazolamide  in 
alcinosis
espuesta  a  acetazolamida  en  pac
o the Editor,
umoural calcinosis (TC) is a rare disorder of phosphorus
etabolism, characterised by the formation of periarticular
eposits of calcium phosphate.1 The disease is the result of
 defect in renal phosphorus excretion, due to mutations
n the genes for ﬁbroblast growth factor 23 (FGF23), Klotho
KL), and N-acetylgalactosaminyltransferase-3 (GALNT3). The
oss of FGF23 function results in increased tubular phospho-
us reabsorption, and subsequent deposition in subcutaneous
isses.2
We  present the case of a 23-year-old man  with no signiﬁ-
ant past medical history, whose symptoms began at the age
f 18 years, with the appearance of a mass in the right dor-
al region, lateral buttock, and thigh. The patient reported a
rogressive increase in size of the mass, related with physical
ctivity, and pain in the affected limb as a functional limi-
ation. Six months before his admission to our hospital, the
umour had been excised, measuring 18 × 7 cm from the right
high, and 20 × 10 cm from the right buttock, with amorphous
haracteristics.
On admission, he had a solid painless mass in the area
f excision on the superﬁcial lateral right thigh, measuring
0 × 4 × 6 cm.  Laboratory analysis reported normal serum lev-
ls of calcium, phosphate, creatinine, albumin, and PTH. X-ray
evealed a multinodular calciﬁed mass around the right hip
oint.
Biopsy of the lesion reported amorphous calciﬁed nod-
les, some surrounded by a proliferation of macrophages and
DOI of original article:
ttp://dx.doi.org/10.1016/j.nefro.2015.07.002.
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http://dx.doi.org/10.1016/j.nefro.2015.06.002patient  with  tumoural
te  con  calcinosis  tumoral
osteoclast-like giant cells, separated by dense ﬁbrous tissue,
consistent with TC (Fig. 1). He was followed up for 2 years
while receiving acetazolamide (August 2008 to October 2011)
and showed clinical improvement and cessation of growth of
the lesions. There were no reported acid–base disturbances
during treatment. A follow-up X-ray was taken 7 years after
starting treatment, with no increase in the size of the lesions
(Fig. 2).
The pathophysiology of TC is based on abnormal phospho-
rus metabolism.3 Serum phosphate concentration is regulated
by endocrine communication between bone, kidney, and
the intestine.4 The endocrine factors involved in phosphate
metabolism are 1,25-hydroxyvitamin D3, parathyroid hor-
mone (PTH) and FGF23. FGF23 and PTH act synergistically to
reduce the expression of the cotransporters NaPi-IIa and NaPi-
IIc in the brush border of the proximal renal tubule, increasing
renal phosphorus excretion.5
FGF 23 is a glycoprotein, formed by 251 amino acids, and
has an N-terminal and a C-terminal made of 71 amino acids.6
It promotes phosphorus excretion by reducing the expression
of NaP(i) cotransporters in the proximal tubular cell brush
border.3 For FGF23 to bind to its receptor, FGFR1c, Klotho is
essential to form a functional heterodimer.7 FGF23 is gly-
cosylated by GALNT3.8 Only the complete FGF23 protein is
biologically active. Therefore, an abnormality at any of thesega E, Chamizo-Aguilar K. Respuesta a acetazolamida en paciente
which is what happens in TC.3
The disease manifests as hyperphosphatemia and massive
calcium deposition in the subcutaneous tissue, which are the
